161 related articles for article (PubMed ID: 33040780)
1. Investigating the changes in the levels of HbA1c, blood fat and insulin sensitivity in elder patients with type II diabetes mellitus due to combined medication of pioglitazone and melbine and single-use of pioglitazone.
Sun Y; Yu Q; Xie J
Cell Mol Biol (Noisy-le-grand); 2020 Sep; 66(6):21-28. PubMed ID: 33040780
[TBL] [Abstract][Full Text] [Related]
2. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
3. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
4. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
de Winter W; DeJongh J; Post T; Ploeger B; Urquhart R; Moules I; Eckland D; Danhof M
J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):313-43. PubMed ID: 16552630
[TBL] [Abstract][Full Text] [Related]
5. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
Erdem G; Dogru T; Tasci I; Bozoglu E; Muhsiroglu O; Tapan S; Ercin CN; Sonmez A
Diabetes Res Clin Pract; 2008 Nov; 82(2):214-8. PubMed ID: 18778865
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome.
Kutoh E
Endocr Res; 2010; 35(3):118-27. PubMed ID: 20712426
[TBL] [Abstract][Full Text] [Related]
7. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
8. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
Mori Y; Itoh Y; Obata T; Tajima N
Endocrine; 2006 Feb; 29(1):143-8. PubMed ID: 16622303
[TBL] [Abstract][Full Text] [Related]
9. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
[TBL] [Abstract][Full Text] [Related]
10. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
[TBL] [Abstract][Full Text] [Related]
11. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
12. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
Stringer F; DeJongh J; Enya K; Koumura E; Danhof M; Kaku K
Diabetes Technol Ther; 2015 Mar; 17(3):215-23. PubMed ID: 25531677
[TBL] [Abstract][Full Text] [Related]
14. The possible correlation between serum GRB2 levels and carotid atherosclerosis in patients with type 2 diabetes mellitus.
Dong Y; Liu J; Ma J; Quan J; Bao Y; Cui Y
Front Endocrinol (Lausanne); 2022; 13():963191. PubMed ID: 36176460
[TBL] [Abstract][Full Text] [Related]
15. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.
Perriello G; Pampanelli S; Di Pietro C; Brunetti P;
Diabet Med; 2006 Mar; 23(3):246-52. PubMed ID: 16492206
[TBL] [Abstract][Full Text] [Related]
16. Clinical Efficacy and Safety of Liraglutide and Dapagliflozin on Glucose and Lipid Metabolism and Insulin Function in Patients with Type 2 Diabetes Mellitus.
Ma J; Fu J; Guo N; Liu Z
Altern Ther Health Med; 2024 Jan; ():. PubMed ID: 38294744
[TBL] [Abstract][Full Text] [Related]
17. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
Sharma SK; Verma SH
J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
[TBL] [Abstract][Full Text] [Related]
19. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
Charpentier G; Halimi S;
Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients.
Genovese S; Passaro A; Brunetti P; Comaschi M; Cucinotta D; ; Egan CG; Chinea B; Bravi F; Di Pietro C
J Endocrinol Invest; 2013 Sep; 36(8):606-16. PubMed ID: 23511244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
